Will Abbott's Split Unlock Shareholder Value? Seeking Alpha Daclizumab, previously approved in Europe to prevent rejection of organ transplants, is in a Phase 3 trial to examine its efficacy as a multiple sclerosis (MS) treatment. Abbott has three compounds in Phase 2 trials for the treatment of hepatitis C, ... |
